Skip to main content

BioVenture — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

279
Companies
$2.1B
Total invested
$23.9M
Avg. check
20
Industries
Biotechnology 17Health Care 14Medical 11Therapeutics 11Biopharma 7Pharmaceutical 4+14 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 279
Estuary Biotherapeutics
October 2026

Estuary Biotherapeutics is a biotechnology company developing genetic medicines for serious kidney diseases.

Biotechnology · San Francisco$93.0M Series A
Altay Therapeutics
October 2026

Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for chronic inflammatory conditions.

Biotechnology · San Francisco$37.0M Series A
Vaxcyte
October 2026

Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Biopharma · San Carlos$575.0M Post-IPO Debt
AnaCardio
September 2026

AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.

Biopharma · Solna$70.8M Series B
Tempo Therapeutics
September 2026

Tempo Therapeutics develops materials that are immune stealth, minimally invasive, and precision-engineered for regenerative medicine.

Biotechnology · San Diego$2.3M Grant
AusperBio
August 2026

AusperBio is a biotechnology company focused on developing oligonucleotide therapeutics and targeted delivery technologies.

Biopharma · San Mateo$120.0M Series C
BRAINBox Solutions
August 2026

BRAINBox provides objective evidence of injury and prediction of patient recovery.

Biotechnology · Richmond$7.1M Venture - Series Unknown
LB Pharmaceuticals
July 2026

LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.

Biopharma · New York$150.0M Post-IPO Equity
Cornea Sense
July 2026

CorneaSense is a medtech startup developing a non-invasive eye sensor to measure ocular hydration for early disease detection.

Health Diagnostics · Espoo$1.3M Pre-Seed
Commons Clinic
July 2026

Commons Clinic is a multi-specialty clinic offering minimally-invasive surgical and conservative musculoskeletal care.

Health Care · Los Angeles$10.1M Venture - Series Unknown
Tavo Biotherapeutics
June 2026

Tavo Biotherapeutics is a biotech company that develops injection therapies for eye diseases.

Biotechnology · Dorchester$17.0M Series A
Rivermark Medical
May 2026

Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function.

Health Care · Milwaukee$20.0M Series D
Brano Therapeutics
May 2026

Brano Therapeutics is a biotech developing therapies for cardio-metabolic and heart failure diseases.

Singapore$6.8M Seed
Heranova Lifesciences
March 2026

Heranova is developing innovative diagnostics and treatments designed to improve women's health and address reproductive challenges

Health Care · BurlingtonSeries A
Excalipoint Therapetics
March 2026

Excalipoint Therapeutics develops targeted therapies that focus on modulating disease pathways at specific biological points.

Biotechnology · Admiralty$27.7M Seed
Theolytics
March 2026

Theolytics is a clinical stage biotechnology company developing next-generation viral therapies.

Biotechnology · Oxford$9.3M Grant
Aegle Therapeutics
March 2026

Aegle Therapeutics is a clinical-stage regenerative medicine company that develops novel therapeutics.

Biotechnology · Miami$456K Debt Financing
Psivant Therapeutics
December 2025

Psivant Therapeutics is a biotechnology company that offers drug design, biology research, and development services.

Biopharma · Watertown$47.5M Series A
NanoMosaic
November 2025

NanoMosaic provides solutions for early illness detection, prognostic monitoring, and biomarker identification.

Biopharma · Waltham$3.0M Venture - Series Unknown
BOOST Pharma
November 2025

BOOST Pharma develops a stem cell therapy for the treatment of osteogenesis imperfecta.

Biopharma · Copenhagen$3.6M Venture - Series Unknown
Pelage Pharmaceuticals
October 2025

Pelage Pharma is a regenerative medicine biotechnology company developing treatments for hair loss.

Health Care · Los Angeles$120.0M Series B
Tianhu Technology
March 2026

Tianhu Technology is a computational chemistry and AI-driven innovative drug molecule design provider.

Alternative Protein · Minhang$29.0M Series A
AccuPulse
March 2026

AccuPulse is developing novel pulsed electric field ablation (PFA) generator and catheters.

Health Care · Suzhou$14.5M Series B
Yili Pharmaceutical
March 2026

Yili Pharmaceutical is a pharmaceutical R&D company.

Biotechnology · Hangzhou$14.5M Seed

Where BioVenture invests

Biotechnology17
Health Care14
Medical11
Therapeutics11
Biopharma7
Pharmaceutical4

About BioVenture's portfolio

How many companies has BioVenture invested in?▸

BioVenture has invested in 279 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does BioVenture invest in?▸

BioVenture's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Biopharma. The firm invests across 20 different industry categories.

What is BioVenture's largest investment?▸

Among tracked funding rounds, Vaxcyte received $575.0M in a Post-IPO Debt round. BioVenture's total known invested capital is $2.1B.

What is the average investment size for BioVenture?▸

BioVenture's average investment size is $23.9M across its portfolio of 279 companies.

What are BioVenture's most recent investments?▸

Recent BioVenture portfolio additions include Estuary Biotherapeutics, Altay Therapeutics, Vaxcyte, AnaCardio, Tempo Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 279 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →